The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: A multicenter clinical trial

Clinical Breast Cancer

Volumn 15, Issue 2, 2015, Pages 110-116

  Shigematsu, Hideo ^a   Kadoya, Takayuki ^a   Masumoto, Norio ^a   Sasada, Tatsunari ^b   Emi, Akiko ^a   Ohara, Masahiro ^c   Kajitani, Keiko ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Onomichi General Hospital   (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

Abraxane; Breast cancer; Cyclophosphamide; Preoperative chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ALBUMIN-BOUND PACLITAXEL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY;

EID: 84924902205     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.09.010     Document Type: Article

References (25)

1. H.D. Bear, S. Anderson, and R.E. Smith Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2006 2019 2027
2. L. Gianni, W. Eiermann, and V. Semiglazov Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet Oncol 15 2014 640 647
3. P. Rastogi, S.J. Anderson, and H.D. Bear Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 2008 778 785
4. L. Gianni, W. Eiermann, and V. Semiglazov Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
5. J.R. Gralow, H.J. Burstein, and W. Wood Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 2008 814 819
6. M. Kaufmann, G.N. Hortobagyi, and A. Goldhirsch Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 2006 1940 1949
7. W.M. Sikov, D.S. Dizon, and R. Strenger Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study J Clin Oncol 27 2009 4693 4700
8. G. von Minckwitz, M. Rezai, and S. Loibl Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study J Clin Oncol 28 2010 2015 2023
9. X.S. Chen, X.Q. Nie, and C.M. Chen Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer Ann Oncol 21 2010 961 967
10. H.D. Bear, G. Tang, and P. Rastogi Bevacizumab added to neoadjuvant chemotherapy for breast cancer N Engl J Med 366 2012 310 320
11. G. von Minckwitz, H. Eidtmann, and M. Rezai Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer N Engl J Med 366 2012 299 309
12. S. Ohno, L.W. Chow, and N. Sato Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil- epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy Breast Cancer Res Treat 142 2013 69 80
13. H.M. Earl, A.L. Vallier, and L. Hiller Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial Lancet Oncol 15 2014 201 212
14. N.K. Ibrahim, N. Desai, and S. Legha Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 2002 1038 1044
15. N. Desai, V. Trieu, and Z. Yao Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 2006 1317 1324
16. M. Foote Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel Biotechnol Annu Rev 13 2007 345 357
17. W.J. Gradishar, S. Tjulandin, and N. Davidson Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803
18. S.E. Jones, M.A. Savin, and F.A. Holmes Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 2006 5381 5387
19. S. Jones, F.A. Holmes, and J. O'Shaughnessy Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 2009 1177 1183
20. S.E. Jones, R. Collea, and D. Paul Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study Lancet Oncol 14 2013 1121 1128
21. D. Yardley, H. Burris 3rd, and N. Peacock A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer Breast Cancer Res Treat 123 2010 471 475
22. W.J. Gradishar, D. Krasnojon, and S. Cheporov Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 2009 3611 3619
23. H.S. Rugo, W.T. Barry, and A. Moreno-Aspitia CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) ( CRA1002) J Clin Oncol 30 2012
24. L.J. Esserman, D.A. Berry, and A. DeMichele Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657 J Clin Oncol 30 2012 3242 3249
25. P. Cortazar, L. Zhang, and M. Untch Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 2014 164 172